{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:50:25Z","timestamp":1792641025860,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1810523"],"award-info":[{"award-number":["W81XWH1810523"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bone metastatic prostate cancer (PCa) promotes mesenchymal stem cell (MSC) recruitment and their differentiation into osteoblasts. However, the effects of bone-marrow derived MSCs on PCa cells are less explored. Here, we report MSC-derived interleukin-28 (IL-28) triggers prostate cancer cell apoptosis via IL-28 receptor alpha (IL-28R\u03b1)-STAT1 signaling. However, chronic exposure to MSCs drives the selection of prostate cancer cells that are resistant to IL-28-induced apoptosis and therapeutics such as docetaxel. Further, MSC-selected\/IL-28-resistant prostate cancer cells grow at accelerated rates in bone. Acquired resistance to apoptosis is PCa cell intrinsic, and is associated with a shift in IL-28R\u03b1 signaling via STAT1 to STAT3. Notably, STAT3 ablation or inhibition impairs MSC-selected prostate cancer cell growth and survival. Thus, bone marrow MSCs drive the emergence of therapy-resistant bone metastatic prostate cancer yet this can be disabled by targeting STAT3.<\/jats:p>","DOI":"10.1038\/s41467-021-20962-6","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T11:06:44Z","timestamp":1612177604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Jeremy J.","family":"McGuire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2181-1836","authenticated-orcid":false,"given":"Jeremy S.","family":"Frieling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-2507","authenticated-orcid":false,"given":"Chen Hao","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaz","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshani R.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1129-2558","authenticated-orcid":false,"given":"Nicholas J.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-6244","authenticated-orcid":false,"given":"Conor C.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"20962_CR1","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31, 578\u2013583 (2000).","journal-title":"Hum. Pathol."},{"key":"20962_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med 351, 1513\u20131520 (2004).","journal-title":"N. Engl. J. Med"},{"key":"20962_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/107327481502200114","volume":"22","author":"JS Frieling","year":"2015","unstructured":"Frieling, J. S., Basanta, D. & Lynch, C. C. Current and emerging therapies for bone metastatic castration-resistant prostate cancer. Cancer Control. 22, 109\u2013120 (2015).","journal-title":"Cancer Control."},{"key":"20962_CR4","doi-asserted-by":"publisher","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","volume":"12","author":"TA Guise","year":"2006","unstructured":"Guise, T. A. et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 12, 6213s\u20136216s (2006).","journal-title":"Clin. Cancer Res"},{"key":"20962_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher, K. N., Guise, T. A. & McCauley, L. K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411\u2013425 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"20962_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1046\/j.1365-2141.2003.04284.x","volume":"121","author":"SA Wexler","year":"2003","unstructured":"Wexler, S. A. et al. Adult bone marrow is a rich source of human mesenchymal \u2018stem\u2019 cells but umbilical cord and mobilized adult blood are not. Br. J. Haematol. 121, 368\u2013374 (2003).","journal-title":"Br. J. Haematol."},{"key":"20962_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2014.11.017","volume":"27","author":"H Wang","year":"2015","unstructured":"Wang, H. et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell 27, 193\u2013210 (2015).","journal-title":"Cancer Cell"},{"key":"20962_CR8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00109-015-1329-4","volume":"93","author":"G Ren","year":"2015","unstructured":"Ren, G., Esposito, M. & Kang, Y. Bone metastasis and the metastatic niche. J. Mol. Med. (Berl.) 93, 1203\u20131212 (2015).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"20962_CR9","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1002\/jcb.23258","volume":"112","author":"V Fritz","year":"2011","unstructured":"Fritz, V. et al. Bone-metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential. J. Cell Biochem. 112, 3234\u20133245 (2011).","journal-title":"J. Cell Biochem"},{"key":"20962_CR10","doi-asserted-by":"publisher","first-page":"30015","DOI":"10.3390\/ijms161226215","volume":"16","author":"KJ Rhee","year":"2015","unstructured":"Rhee, K. J., Lee, J. I. & Eom, Y. W. Mesenchymal stem cell-mediated effects of tumor support or suppression. Int J. Mol. Sci. 16, 30015\u201330033 (2015).","journal-title":"Int J. Mol. Sci."},{"key":"20962_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/stem.559","volume":"29","author":"AH Klopp","year":"2011","unstructured":"Klopp, A. H., Gupta, A., Spaeth, E., Andreeff, M. & Marini, F. 3rd Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 29, 11\u201319 (2011).","journal-title":"Stem Cells"},{"key":"20962_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/scrt322","volume":"4","author":"I Atsuta","year":"2013","unstructured":"Atsuta, I. et al. Mesenchymal stem cells inhibit multiple myeloma cells via the Fas\/Fas ligand pathway. Stem cell Res. Ther. 4, 111 (2013).","journal-title":"Stem cell Res. Ther."},{"key":"20962_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nature06188","volume":"449","author":"AE Karnoub","year":"2007","unstructured":"Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557\u2013563 (2007).","journal-title":"Nature"},{"key":"20962_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/gutjnl-2011-301393","volume":"62","author":"A De Boeck","year":"2013","unstructured":"De Boeck, A. et al. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1\/HER3 signalling. Gut 62, 550\u2013560 (2013).","journal-title":"Gut"},{"key":"20962_CR15","doi-asserted-by":"crossref","unstructured":"Mi F. & Gong L. Secretion of interleukin-6 by bone marrow mesenchymal stem cells promotes metastasis in hepatocellular carcinoma. Biosci Rep 37, BSR20170181 (2017).","DOI":"10.1042\/BSR20170181"},{"key":"20962_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0366-7","volume":"9","author":"C Zong","year":"2018","unstructured":"Zong, C. et al. The distinct roles of mesenchymal stem cells in the initial and progressive stage of hepatocarcinoma. Cell Death Dis. 9, 345 (2018).","journal-title":"Cell Death Dis."},{"key":"20962_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0597-8","volume":"16","author":"SM Ridge","year":"2017","unstructured":"Ridge, S. M., Sullivan, F. J. & Glynn, S. A. Mesenchymal stem cells: key players in cancer progression. Mol. Cancer 16, 31 (2017).","journal-title":"Mol. Cancer"},{"key":"20962_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.coi.2011.07.007","volume":"23","author":"SV Kotenko","year":"2011","unstructured":"Kotenko, S. V. IFN-lambdas. Curr. Opin. Immunol. 23, 583\u2013590 (2011).","journal-title":"Curr. Opin. Immunol."},{"key":"20962_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5582\/bst.2016.01250","volume":"11","author":"K Friedrich","year":"2017","unstructured":"Friedrich, K., Dolznig, H., Han, X. & Moriggl, R. Steering of carcinoma progression by the YIN\/YANG interaction of STAT1\/STAT3. Biosci. Trends 11, 1\u20138 (2017).","journal-title":"Biosci. Trends"},{"key":"20962_CR20","doi-asserted-by":"crossref","unstructured":"Santoni M. et al. Role of STAT3 pathway in genitourinary tumors. Future Sci. OA 1, FSO15 (2015).","DOI":"10.4155\/fso.15.13"},{"key":"20962_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.eururo.2016.06.018","volume":"71","author":"N Don-Doncow","year":"2017","unstructured":"Don-Doncow, N. et al. Expression of STAT3 in prostate cancer metastases. Eur. Urol. 71, 313\u2013316 (2017).","journal-title":"Eur. Urol."},{"key":"20962_CR22","doi-asserted-by":"publisher","first-page":"E4762","DOI":"10.1073\/pnas.1319948110","volume":"110","author":"JM Drake","year":"2013","unstructured":"Drake, J. M. et al. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc. Natl Acad. Sci. USA 110, E4762\u2013E4769 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"20962_CR23","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.juro.2008.04.140","volume":"180","author":"MP Roudier","year":"2008","unstructured":"Roudier, M. P. et al. Histopathological assessment of prostate cancer bone osteoblastic metastases. J. Urol. 180, 1154\u20131160 (2008).","journal-title":"J. Urol."},{"key":"20962_CR24","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1038\/onc.2013.233","volume":"33","author":"J Luo","year":"2014","unstructured":"Luo, J. et al. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene 33, 2768\u20132778 (2014).","journal-title":"Oncogene"},{"key":"20962_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.18632\/oncotarget.805","volume":"4","author":"WN Brennen","year":"2013","unstructured":"Brennen, W. N., Chen, S., Denmeade, S. R. & Isaacs, J. T. Quantification of mesenchymal stem cells (MSCs) at sites of human prostate cancer. Oncotarget 4, 106\u2013117 (2013).","journal-title":"Oncotarget"},{"key":"20962_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ymeth.2015.09.016","volume":"99","author":"J Kobolak","year":"2016","unstructured":"Kobolak, J., Dinnyes, A., Memic, A., Khademhosseini, A. & Mobasheri, A. Mesenchymal stem cells: Identification, phenotypic characterization, biological properties and potential for regenerative medicine through biomaterial micro-engineering of their niche. Methods 99, 62\u201368 (2016).","journal-title":"Methods"},{"key":"20962_CR27","doi-asserted-by":"publisher","first-page":"762098","DOI":"10.1155\/2015\/762098","volume":"2015","author":"L Xie","year":"2015","unstructured":"Xie, L., Zeng, X., Hu, J. & Chen, Q. Characterization of nestin, a selective marker for bone marrow derived mesenchymal stem cells. Stem Cells Int 2015, 762098 (2015).","journal-title":"Stem Cells Int"},{"key":"20962_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/srep29384","volume":"6","author":"LM Cook","year":"2016","unstructured":"Cook, L. M. et al. Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer. Sci. Rep. 6, 29384 (2016).","journal-title":"Sci. Rep."},{"key":"20962_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jss.2003.10.022","volume":"120","author":"JP Hodde","year":"2004","unstructured":"Hodde, J. P., Suckow, M. A., Wolter, W. R. & Hiles, M. C. Small intestinal submucosa does not promote PAIII tumor growth in Lobund-Wistar rats. J. Surg. Res 120, 189\u2013194 (2004).","journal-title":"J. Surg. Res"},{"key":"20962_CR30","doi-asserted-by":"crossref","unstructured":"Luhach I. et al. Rapid ex vivo imaging of PAIII prostate to bone tumor with SWIFT-MRI. Magn. Reson. Med. 72, 858\u2013863 (2014).","DOI":"10.1002\/mrm.24979"},{"key":"20962_CR31","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1158\/0008-5472.CAN-13-2652","volume":"74","author":"A Araujo","year":"2014","unstructured":"Araujo, A., Cook, L. M., Lynch, C. C. & Basanta, D. An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer. Cancer Res. 74, 2391\u20132401 (2014).","journal-title":"Cancer Res."},{"key":"20962_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.lungcan.2012.09.005","volume":"78","author":"Y Tezuka","year":"2012","unstructured":"Tezuka, Y. et al. Potential anti-tumor effect of IFN-lambda2 (IL-28A) against human lung cancer cells. Lung Cancer 78, 185\u2013192 (2012).","journal-title":"Lung Cancer"},{"key":"20962_CR33","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2741\/4152","volume":"18","author":"Q Li","year":"2013","unstructured":"Li, Q. et al. Novel type III interferons produce anti-tumor effects through multiple functions. Front. Biosci. (Landmark Ed.) 18, 909\u2013918 (2013).","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"20962_CR34","first-page":"12509","volume":"8","author":"B Song","year":"2015","unstructured":"Song, B. et al. Adenovirus expressing IFN-lambda (Ad\/hIFN-lambda) produced anti-tumor effects through inducing apoptosis in human tongue squamous cell carcinoma cell. Int J. Clin. Exp. Med. 8, 12509\u201312518 (2015).","journal-title":"Int J. Clin. Exp. Med."},{"key":"20962_CR35","doi-asserted-by":"publisher","first-page":"L89","DOI":"10.1152\/ajplung.00200.2016","volume":"312","author":"JL Girkin","year":"2017","unstructured":"Girkin, J. L. et al. TRAIL signaling is proinflammatory and proviral in a murine model of rhinovirus 1B infection. Am. J. Physiol. Lung Cell Mol. Physiol. 312, L89\u2013L99 (2017).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"20962_CR36","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1111\/febs.13285","volume":"282","author":"MS Wake","year":"2015","unstructured":"Wake, M. S. & Watson, C. J. STAT3 the oncogene - still eluding therapy? FEBS J. 282, 2600\u20132611 (2015).","journal-title":"FEBS J."},{"key":"20962_CR37","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3389\/fendo.2017.00361","volume":"8","author":"SR Hubbard","year":"2017","unstructured":"Hubbard, S. R. Mechanistic insights into regulation of JAK2 tyrosine kinase. Front. Endocrinol. (Lausanne) 8, 361 (2017).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"20962_CR38","doi-asserted-by":"publisher","first-page":"7391","DOI":"10.1073\/pnas.0609757104","volume":"104","author":"K Siddiquee","year":"2007","unstructured":"Siddiquee, K. et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl Acad. Sci. USA 104, 7391\u20137396 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"20962_CR39","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.1158\/0008-5472.CAN-15-1215","volume":"75","author":"YC Lee","year":"2015","unstructured":"Lee, Y. C. et al. Identification of bone-derived factors conferring de novo therapeutic resistance in metastatic prostate cancer. Cancer Res 75, 4949\u20134959 (2015).","journal-title":"Cancer Res"},{"key":"20962_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10555-017-9719-4","volume":"37","author":"C Logothetis","year":"2018","unstructured":"Logothetis, C., Morris, M. J., Den, R. & Coleman, R. E. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev. 37, 189\u2013196 (2018).","journal-title":"Cancer Metastasis Rev."},{"key":"20962_CR41","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3892\/mmr.2013.1698","volume":"8","author":"F Jin","year":"2013","unstructured":"Jin, F. et al. Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling. Mol. Med. Rep. 8, 1486\u20131492 (2013).","journal-title":"Mol. Med. Rep."},{"key":"20962_CR42","doi-asserted-by":"publisher","first-page":"e4992","DOI":"10.1371\/journal.pone.0004992","volume":"4","author":"EL Spaeth","year":"2009","unstructured":"Spaeth, E. L. et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 4, e4992 (2009).","journal-title":"PLoS ONE"},{"key":"20962_CR43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.canlet.2009.02.022","volume":"281","author":"WT Xu","year":"2009","unstructured":"Xu, W. T., Bian, Z. Y., Fan, Q. M., Li, G. & Tang, T. T. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett. 281, 32\u201341 (2009).","journal-title":"Cancer Lett."},{"key":"20962_CR44","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1182\/blood.V99.7.2532","volume":"99","author":"S Dias","year":"2002","unstructured":"Dias, S., Shmelkov, S. V., Lam, G. & Rafii, S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 99, 2532\u20132540 (2002).","journal-title":"Blood"},{"key":"20962_CR45","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.leu.2400556","volume":"11","author":"A Konig","year":"1997","unstructured":"Konig, A. et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11, 258\u2013265 (1997).","journal-title":"Leukemia"},{"key":"20962_CR46","doi-asserted-by":"publisher","first-page":"85997","DOI":"10.18632\/oncotarget.20844","volume":"8","author":"SK Mohanty","year":"2017","unstructured":"Mohanty, S. K. et al. STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer. Oncotarget 8, 85997\u201386010 (2017).","journal-title":"Oncotarget"},{"key":"20962_CR47","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/sj.leu.2404489","volume":"21","author":"R Ramasamy","year":"2007","unstructured":"Ramasamy, R. et al. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 21, 304\u2013310 (2007).","journal-title":"Leukemia"},{"key":"20962_CR48","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.canlet.2014.06.018","volume":"352","author":"H Ryu","year":"2014","unstructured":"Ryu, H. et al. Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN-beta and suppress the growth of MCF-7 human breast cancer cells. Cancer Lett. 352, 220\u2013227 (2014).","journal-title":"Cancer Lett."},{"key":"20962_CR49","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1593\/neo.13706","volume":"15","author":"Q Chang","year":"2013","unstructured":"Chang, Q. et al. The IL-6\/JAK\/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 15, 848\u2013862 (2013).","journal-title":"Neoplasia"},{"key":"20962_CR50","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson, D. E., O\u2019Keefe, R. A. & Grandis, J. R. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234\u2013248 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"20962_CR51","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.2353\/ajpath.2008.071054","volume":"172","author":"J Abdulghani","year":"2008","unstructured":"Abdulghani, J. et al. Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172, 1717\u20131728 (2008).","journal-title":"Am. J. Pathol."},{"key":"20962_CR52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.canlet.2006.10.017","volume":"251","author":"DA Frank","year":"2007","unstructured":"Frank, D. A. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251, 199\u2013210 (2007).","journal-title":"Cancer Lett."},{"key":"20962_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8736","volume":"6","author":"J Pencik","year":"2015","unstructured":"Pencik, J. et al. STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat. Commun. 6, 7736 (2015).","journal-title":"Nat. Commun."},{"key":"20962_CR54","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1158\/0008-5472.CAN-05-3653","volume":"66","author":"A Lasfar","year":"2006","unstructured":"Lasfar, A. et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 66, 4468\u20134477 (2006).","journal-title":"Cancer Res"},{"key":"20962_CR55","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/S0960-9822(00)80113-X","volume":"9","author":"WC Powell","year":"1999","unstructured":"Powell, W. C., Fingleton, B., Wilson, C. L., Boothby, M. & Matrisian, L. M. The metalloproteinase matrilysin (MMP-7) proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. 9, 1441\u20131447 (1999).","journal-title":"Curr. Biol."},{"key":"20962_CR56","first-page":"5559","volume":"62","author":"T Vargo-Gogola","year":"2002","unstructured":"Vargo-Gogola, T., Fingleton, B., Crawford, H. C. & Matrisian, L. M. Matrilysin (matrix metalloproteinase-7) selects for apoptosis-resistant mammary cells in vivo. Cancer Res 62, 5559\u20135563 (2002).","journal-title":"Cancer Res"},{"key":"20962_CR57","doi-asserted-by":"crossref","unstructured":"Fingleton, B., Vargo-Gogola, T., Crawford, H. C. & Matrisian, L. M. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3, 459\u2013468 (2001).","DOI":"10.1038\/sj.neo.7900190"},{"key":"20962_CR58","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1172\/JCI0215617","volume":"109","author":"J Bromberg","year":"2002","unstructured":"Bromberg, J. Stat proteins and oncogenesis. J. Clin. Invest 109, 1139\u20131142 (2002).","journal-title":"J. Clin. Invest"},{"key":"20962_CR59","doi-asserted-by":"publisher","first-page":"e20188","DOI":"10.1371\/journal.pone.0020188","volume":"6","author":"V Cimica","year":"2011","unstructured":"Cimica, V., Chen, H. C., Iyer, J. K. & Reich, N. C. Dynamics of the STAT3 transcription factor: nuclear import dependent on Ran and importin-beta1. PLoS One 6, e20188 (2011).","journal-title":"PLoS One"},{"key":"20962_CR60","first-page":"65","volume":"27","author":"V Boeru","year":"1989","unstructured":"Boeru, V., Manea, E. & Olariu, M. [The effect of thymectomy and the polypeptide thymus extract TP2 on the nucleic acid and cholesterol content of the testicle and on serum testosterone in the rat]. Endocrinologie 27, 65\u201371 (1989).","journal-title":"Endocrinologie"},{"key":"20962_CR61","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0014-2999(76)90252-1","volume":"36","author":"BS Jandhyala","year":"1976","unstructured":"Jandhyala, B. S., Cavero, I. & Buckley, J. P. Time-course effects of oral guanethidine administration on cardiovascular and autonomic effects on dogs. Eur. J. Pharm. 36, 21\u201332 (1976).","journal-title":"Eur. J. Pharm."},{"key":"20962_CR62","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jaci.2004.06.042","volume":"114","author":"W Chen","year":"2004","unstructured":"Chen, W., Daines, M. O. & Khurana Hershey, G. K. Turning off signal transducer and activator of transcription (STAT): the negative regulation of STAT signaling. J. Allergy Clin. Immunol. 114, 476\u2013489 (2004). quiz 490.","journal-title":"J. Allergy Clin. Immunol."},{"key":"20962_CR63","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.immuni.2005.04.008","volume":"22","author":"T Tanaka","year":"2005","unstructured":"Tanaka, T., Soriano, M. A. & Grusby, M. J. SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity 22, 729\u2013736 (2005).","journal-title":"Immunity"},{"key":"20962_CR64","doi-asserted-by":"publisher","first-page":"14111","DOI":"10.1074\/jbc.M511797200","volume":"281","author":"HH Ho","year":"2006","unstructured":"Ho, H. H. & Ivashkiv, L. B. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J. Biol. Chem. 281, 14111\u201314118 (2006).","journal-title":"J. Biol. Chem."},{"key":"20962_CR65","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1126\/science.1164551","volume":"323","author":"J Wegrzyn","year":"2009","unstructured":"Wegrzyn, J. et al. Function of mitochondrial Stat3 in cellular respiration. Science 323, 793\u2013797 (2009).","journal-title":"Science"},{"key":"20962_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15342-4","volume":"7","author":"X Cheng","year":"2017","unstructured":"Cheng, X., Peuckert, C. & Wolfl, S. Essential role of mitochondrial Stat3 in p38(MAPK) mediated apoptosis under oxidative stress. Sci. Rep. 7, 15388 (2017).","journal-title":"Sci. Rep."},{"key":"20962_CR67","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fonc.2015.00121","volume":"5","author":"V Poli","year":"2015","unstructured":"Poli, V. & Camporeale, A. STAT3-mediated metabolic reprograming in cellular transformation and implications for drug resistance. Front. Oncol. 5, 121 (2015).","journal-title":"Front. Oncol."},{"key":"20962_CR68","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.yexmp.2005.07.004","volume":"80","author":"W Zhu","year":"2006","unstructured":"Zhu, W. et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp. Mol. Pathol. 80, 267\u2013274 (2006).","journal-title":"Exp. Mol. Pathol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-20962-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-20962-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-20962-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:21:59Z","timestamp":1669976519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-20962-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["20962"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-20962-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"25 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"723"}}